The French pharmaceutical company said it plans to take control of all outstanding shares of Synthorx for $68 per share in cash.
MarketWatch.com - Top Stories, MarketWatch
Mon, 12/09/2019 - 2:07am
The French pharmaceutical company said it plans to take control of all outstanding shares of Synthorx for $68 per share in cash.